Shots:

• The first enrolled patient has received their immunizations as part of a new study in adults ≥65yrs. evaluating the coadministration of 20vPnC with a booster dose of the Pfizer-BioNTech’s COVID-19 vaccine
• The trial will include ~600 adults who will be recruited from the P-III COVID-19 vaccine trial and will have received their second dose of the vaccine at least 6mos. before entering the coadministration study
• The primary objective in the trial is to describe safety when both vaccines are co-administered- with follow up 6mos. after vaccination. The secondary objective is to describe immune responses produced by each of the vaccines

  Ref: Pfizer | Image: Business Wire